Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients

February 14, 2018

Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients

Published on 02/13/2018

previous post: Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab vs ipilimumab alone in patients with advanced, unresectable melanoma
next post: Chronic urinary tract infection and bladder carcinoma risk: A meta-analysis of case–control and cohort studies